Auxilium Pharmaceuticals Inc  

(Public, NASDAQ:AUXL)   Watch this stock  
36.47
After Hours: 36.53 +0.06 (0.16%)
Jan 29, 5:14PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 17.10 - 37.92
Open     -
Vol / Avg. 0.00/1.32M
Mkt cap 1.85B
P/E     -
Div/yield     -
EPS -3.27
Shares 51.02M
Beta 0.66
Inst. own 131%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -29.78% -4.51%
Operating margin -21.16% -16.99%
EBITD margin - -3.47%
Return on average assets -11.59% -2.36%
Return on average equity -76.75% -8.00%
Employees 639 -
CDP Score - -

Address

640 Lee Rd
CHESTERBROOK, PA 19087-5636
United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.